Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison Moskowitz

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Blood Cancer Journal|November 10, 2020
Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological featuresKimon V Argyropoulos, Melissa Pulitzer, Francesco Maura, et al.
Haematologica|August 18, 2025
Two decades of single-institution data reveal rare long-term survivors of relapsed/refractory Burkitt lymphomaRabeya Molla, Kurt Bantilan, Ellin Berman, et al.
Blood Cancer Journal|May 22, 2019
Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapseAnita Kumar, Fushen Sha, Ahmed Toure, et al.
Blood Advances|January 26, 2021
Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissueErel Joffe, Yan Leyfman, Esther Drill, et al.
Blood Advances|October 1, 2020
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphomaPaola Ghione, Promie Faruque, Neha Mehta-Shah, et al.
American Journal of Hematology|November 12, 2019
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomasFrancine M Foss, Steven M Horwitz, Monica Civallero, et al.
Blood|December 14, 2017
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphomaSteven M Horwitz, Raphael Koch, Pierluigi Porcu, et al.
Leukemia & Lymphoma|November 17, 2021
Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experienceTerry K Pak, Brianne N Dixon, Michael J Buege, et al.
Haematologica|March 31, 2018
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell ProjectMonica Bellei, Francine M Foss, Andrei R Shustov, et al.
Haematologica|August 30, 2023
Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomesPaola Ghione, Salma Ahsanuddin, Efrat Luttwak, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Blood Cancer Journal|November 10, 2020
Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological featuresKimon V Argyropoulos, Melissa Pulitzer, Francesco Maura, et al.
Haematologica|August 18, 2025
Two decades of single-institution data reveal rare long-term survivors of relapsed/refractory Burkitt lymphomaRabeya Molla, Kurt Bantilan, Ellin Berman, et al.
Blood Cancer Journal|May 22, 2019
Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapseAnita Kumar, Fushen Sha, Ahmed Toure, et al.
Blood Advances|January 26, 2021
Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissueErel Joffe, Yan Leyfman, Esther Drill, et al.
Blood Advances|October 1, 2020
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphomaPaola Ghione, Promie Faruque, Neha Mehta-Shah, et al.
American Journal of Hematology|November 12, 2019
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomasFrancine M Foss, Steven M Horwitz, Monica Civallero, et al.
Blood|December 14, 2017
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphomaSteven M Horwitz, Raphael Koch, Pierluigi Porcu, et al.
Leukemia & Lymphoma|November 17, 2021
Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experienceTerry K Pak, Brianne N Dixon, Michael J Buege, et al.
Haematologica|March 31, 2018
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell ProjectMonica Bellei, Francine M Foss, Andrei R Shustov, et al.
Haematologica|August 30, 2023
Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomesPaola Ghione, Salma Ahsanuddin, Efrat Luttwak, et al.
Pageof 7